PetVivo Holdings Reports Revenue Growth to $337,572 Despite Net Loss of $1.6M

PetVivo Holdings, Inc. reported its financial results for the three months ending June 30, 2026, revealing a revenue increase to $337,572, up from $297,500 in the same period last year. The growth in revenue was primarily attributed to higher sales of its lead product, Spryng®, which accounted for $208,495 of total sales, compared to $148,243 in the prior year. The company also noted a decline in sales of its Precise PRP products, which generated $129,076 this quarter, down from $149,257 a year ago. Despite the revenue growth, PetVivo recorded a net loss of $1,613,888, a decrease from the $2,311,037 loss reported in the previous year, reflecting improved operational efficiency.

Total operating expenses for the quarter were $1,832,166, down from $2,031,043 in the prior year, driven by reductions in general and administrative and research and development costs. General and administrative expenses decreased to $967,442 from $1,068,818, while research and development expenses fell significantly to $233,419 from $340,513. The company attributed the reduction in R&D spending to tighter cash flow constraints. The operating loss for the quarter was $1,608,849, compared to $1,844,317 in the same period last year, indicating a positive trend in managing operational costs.

As of June 30, 2026, PetVivo's total assets were reported at $2,669,481, a decrease from $3,576,741 as of March 31, 2026. Current assets also fell to $941,019 from $1,709,921, primarily due to a reduction in cash and accounts receivable. The company's current liabilities were $1,313,312, leading to a working capital deficit of $372,293. PetVivo's accumulated deficit increased to $103,051,394, raising concerns about its ability to continue as a going concern without additional capital.

In terms of strategic developments, PetVivo terminated its licensing agreement with VetStem, Inc. on July 24, 2026, which was initially established to market the Precise PRP product. The termination was part of a broader strategy to streamline operations and focus on more profitable product lines. The company is actively seeking additional capital through various financing arrangements, including a potential $10 million investment for its new subsidiary, Cosmeta Corp. PetVivo's management remains focused on improving operational results and increasing revenues to support its ongoing commercialization efforts.

Looking ahead, PetVivo's management expressed uncertainty regarding its ability to secure sufficient financing to support its operations and growth plans. The company plans to continue its efforts to raise capital and improve its financial position, but there can be no assurance of success. The ongoing challenges, including the need for substantial capital and the current working capital deficit, underscore the importance of strategic financial management as PetVivo navigates its path forward in the competitive veterinary market.